Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy
To identify transcriptional profiles predictive of the clinical benefit of cisplatin and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic biopsy samples from 96 CF-treated metastatic gastric cancer patients were prospectively collected before therapy and analyzed using high-thro...
Gespeichert in:
| Veröffentlicht in: | The pharmacogenomics journal 2012-04, Vol.12 (2), p.119-127 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 127 |
|---|---|
| container_issue | 2 |
| container_start_page | 119 |
| container_title | The pharmacogenomics journal |
| container_volume | 12 |
| creator | Kim, H K Choi, I J Kim, C G Kim, H S Oshima, A Yamada, Y Arao, T Nishio, K Michalowski, A Green, J E |
| description | To identify transcriptional profiles predictive of the clinical benefit of cisplatin and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic biopsy samples from 96 CF-treated metastatic gastric cancer patients were prospectively collected before therapy and analyzed using high-throughput transcriptional profiling and array comparative genomic hybridization. Transcriptional profiling identified 917 genes that are correlated with poor patient survival after CF at
P |
| doi_str_mv | 10.1038/tpj.2010.87 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3321506</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A285207846</galeid><sourcerecordid>A285207846</sourcerecordid><originalsourceid>FETCH-LOGICAL-c568t-4b8f4431fd57425d40c35698f7b4bc2f8b7b83a0d4671c3f4b4ab7e2779afec63</originalsourceid><addsrcrecordid>eNp9ks-L1TAQx4so7rp68q5FDwraZ361SS_CsvgLFrys4MmQppO-PNqkm6TK_vemvvXpyiI5JJn5zJeZL1MUjzHaYETFmzTvNgTln-B3imPMOK0wrtHdX29Ukab9elQ8iHGHEG4wF_eLI4Ixp1zw4-LbxTYAVAM4KOcAvdXJh9KbUo_WWa3G0i9J-wlKk-ODiilYXWrlNIRyVsmCS7FMAVSCvvxh07bUW5h82kJQ89XD4p5RY4RH1_dJ8eX9u4uzj9X55w-fzk7PK103IlWsE4Yxik1fc0bqniFN66YVhnes08SIjneCKtSzhmNNDeuY6jgQzltlQDf0pHi7152XboJe566CGuUc7KTClfTKypsZZ7dy8N8lpSR7tQq8uBYI_nKBmORko4ZxVA78EmVbZxDXlGfy5X9JjJAQlNGWZPTZP-jOL8FlI2TLUCsw4XWGnu-hQY0grTM-N6hXTXlKRE0QF2ztb3MLlU8Pk9XegbE5fqPg1b5ABx9jAHMwAyO57o3MeyPXvZFiHerJ3_4d2N-LkoHXeyDmlBsg_Bnldr2ne9yptAQ46GVmRTLxE3pN18c</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>940981275</pqid></control><display><type>article</type><title>Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kim, H K ; Choi, I J ; Kim, C G ; Kim, H S ; Oshima, A ; Yamada, Y ; Arao, T ; Nishio, K ; Michalowski, A ; Green, J E</creator><creatorcontrib>Kim, H K ; Choi, I J ; Kim, C G ; Kim, H S ; Oshima, A ; Yamada, Y ; Arao, T ; Nishio, K ; Michalowski, A ; Green, J E</creatorcontrib><description>To identify transcriptional profiles predictive of the clinical benefit of cisplatin and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic biopsy samples from 96 CF-treated metastatic gastric cancer patients were prospectively collected before therapy and analyzed using high-throughput transcriptional profiling and array comparative genomic hybridization. Transcriptional profiling identified 917 genes that are correlated with poor patient survival after CF at
P
<0.05 (poor prognosis signature), in which protein synthesis and DNA replication/recombination/repair functional categories are enriched. A survival risk predictor was then constructed using genes, which are included in the
poor prognosis signature
and are contained within identified genomic amplicons. The combined expression of three genes—
MYC
,
EGFR
and
FGFR2
—was an independent predictor for overall survival of 27 CF-treated patients in the validation set (adjusted
P
=0.017), and also for survival of 40 chemotherapy-treated gastric cancer patients in a published data set (adjusted
P
=0.026). Thus, combined expression of
MYC
,
EGFR
and
FGFR2
is predictive of poor survival in CF-treated metastatic gastric cancer patients.</description><identifier>ISSN: 1470-269X</identifier><identifier>EISSN: 1473-1150</identifier><identifier>DOI: 10.1038/tpj.2010.87</identifier><identifier>PMID: 21173787</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/208/191/2018 ; 692/699/67/1059/99 ; 692/699/67/1504/1829 ; Aged ; Antineoplastic Agents - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Care and treatment ; Chemotherapy ; Clinical outcomes ; Female ; Gene Expression ; Genes, myc ; Genetic aspects ; Health aspects ; Human Genetics ; Humans ; Male ; Neoplasm Metastasis ; Oncology ; Original ; original-article ; Pharmacotherapy ; Prognosis ; Prospective Studies ; Psychopharmacology ; Receptor, Epidermal Growth Factor - genetics ; Receptor, Fibroblast Growth Factor, Type 2 - genetics ; Risk factors ; Stomach cancer ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - genetics ; Stomach Neoplasms - pathology ; Survival Analysis ; Treatment Outcome</subject><ispartof>The pharmacogenomics journal, 2012-04, Vol.12 (2), p.119-127</ispartof><rights>The Author(s) 2012</rights><rights>COPYRIGHT 2012 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Apr 2012</rights><rights>Copyright © 2012 Macmillan Publishers Limited 2012 Macmillan Publishers Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c568t-4b8f4431fd57425d40c35698f7b4bc2f8b7b83a0d4671c3f4b4ab7e2779afec63</citedby><cites>FETCH-LOGICAL-c568t-4b8f4431fd57425d40c35698f7b4bc2f8b7b83a0d4671c3f4b4ab7e2779afec63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21173787$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, H K</creatorcontrib><creatorcontrib>Choi, I J</creatorcontrib><creatorcontrib>Kim, C G</creatorcontrib><creatorcontrib>Kim, H S</creatorcontrib><creatorcontrib>Oshima, A</creatorcontrib><creatorcontrib>Yamada, Y</creatorcontrib><creatorcontrib>Arao, T</creatorcontrib><creatorcontrib>Nishio, K</creatorcontrib><creatorcontrib>Michalowski, A</creatorcontrib><creatorcontrib>Green, J E</creatorcontrib><title>Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy</title><title>The pharmacogenomics journal</title><addtitle>Pharmacogenomics J</addtitle><addtitle>Pharmacogenomics J</addtitle><description>To identify transcriptional profiles predictive of the clinical benefit of cisplatin and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic biopsy samples from 96 CF-treated metastatic gastric cancer patients were prospectively collected before therapy and analyzed using high-throughput transcriptional profiling and array comparative genomic hybridization. Transcriptional profiling identified 917 genes that are correlated with poor patient survival after CF at
P
<0.05 (poor prognosis signature), in which protein synthesis and DNA replication/recombination/repair functional categories are enriched. A survival risk predictor was then constructed using genes, which are included in the
poor prognosis signature
and are contained within identified genomic amplicons. The combined expression of three genes—
MYC
,
EGFR
and
FGFR2
—was an independent predictor for overall survival of 27 CF-treated patients in the validation set (adjusted
P
=0.017), and also for survival of 40 chemotherapy-treated gastric cancer patients in a published data set (adjusted
P
=0.026). Thus, combined expression of
MYC
,
EGFR
and
FGFR2
is predictive of poor survival in CF-treated metastatic gastric cancer patients.</description><subject>631/208/191/2018</subject><subject>692/699/67/1059/99</subject><subject>692/699/67/1504/1829</subject><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Genes, myc</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Male</subject><subject>Neoplasm Metastasis</subject><subject>Oncology</subject><subject>Original</subject><subject>original-article</subject><subject>Pharmacotherapy</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Psychopharmacology</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Receptor, Fibroblast Growth Factor, Type 2 - genetics</subject><subject>Risk factors</subject><subject>Stomach cancer</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - genetics</subject><subject>Stomach Neoplasms - pathology</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>1470-269X</issn><issn>1473-1150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9ks-L1TAQx4so7rp68q5FDwraZ361SS_CsvgLFrys4MmQppO-PNqkm6TK_vemvvXpyiI5JJn5zJeZL1MUjzHaYETFmzTvNgTln-B3imPMOK0wrtHdX29Ukab9elQ8iHGHEG4wF_eLI4Ixp1zw4-LbxTYAVAM4KOcAvdXJh9KbUo_WWa3G0i9J-wlKk-ODiilYXWrlNIRyVsmCS7FMAVSCvvxh07bUW5h82kJQ89XD4p5RY4RH1_dJ8eX9u4uzj9X55w-fzk7PK103IlWsE4Yxik1fc0bqniFN66YVhnes08SIjneCKtSzhmNNDeuY6jgQzltlQDf0pHi7152XboJe566CGuUc7KTClfTKypsZZ7dy8N8lpSR7tQq8uBYI_nKBmORko4ZxVA78EmVbZxDXlGfy5X9JjJAQlNGWZPTZP-jOL8FlI2TLUCsw4XWGnu-hQY0grTM-N6hXTXlKRE0QF2ztb3MLlU8Pk9XegbE5fqPg1b5ABx9jAHMwAyO57o3MeyPXvZFiHerJ3_4d2N-LkoHXeyDmlBsg_Bnldr2ne9yptAQ46GVmRTLxE3pN18c</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Kim, H K</creator><creator>Choi, I J</creator><creator>Kim, C G</creator><creator>Kim, H S</creator><creator>Oshima, A</creator><creator>Yamada, Y</creator><creator>Arao, T</creator><creator>Nishio, K</creator><creator>Michalowski, A</creator><creator>Green, J E</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120401</creationdate><title>Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy</title><author>Kim, H K ; Choi, I J ; Kim, C G ; Kim, H S ; Oshima, A ; Yamada, Y ; Arao, T ; Nishio, K ; Michalowski, A ; Green, J E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c568t-4b8f4431fd57425d40c35698f7b4bc2f8b7b83a0d4671c3f4b4ab7e2779afec63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>631/208/191/2018</topic><topic>692/699/67/1059/99</topic><topic>692/699/67/1504/1829</topic><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Genes, myc</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Male</topic><topic>Neoplasm Metastasis</topic><topic>Oncology</topic><topic>Original</topic><topic>original-article</topic><topic>Pharmacotherapy</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Psychopharmacology</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Receptor, Fibroblast Growth Factor, Type 2 - genetics</topic><topic>Risk factors</topic><topic>Stomach cancer</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - genetics</topic><topic>Stomach Neoplasms - pathology</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, H K</creatorcontrib><creatorcontrib>Choi, I J</creatorcontrib><creatorcontrib>Kim, C G</creatorcontrib><creatorcontrib>Kim, H S</creatorcontrib><creatorcontrib>Oshima, A</creatorcontrib><creatorcontrib>Yamada, Y</creatorcontrib><creatorcontrib>Arao, T</creatorcontrib><creatorcontrib>Nishio, K</creatorcontrib><creatorcontrib>Michalowski, A</creatorcontrib><creatorcontrib>Green, J E</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The pharmacogenomics journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, H K</au><au>Choi, I J</au><au>Kim, C G</au><au>Kim, H S</au><au>Oshima, A</au><au>Yamada, Y</au><au>Arao, T</au><au>Nishio, K</au><au>Michalowski, A</au><au>Green, J E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy</atitle><jtitle>The pharmacogenomics journal</jtitle><stitle>Pharmacogenomics J</stitle><addtitle>Pharmacogenomics J</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>12</volume><issue>2</issue><spage>119</spage><epage>127</epage><pages>119-127</pages><issn>1470-269X</issn><eissn>1473-1150</eissn><abstract>To identify transcriptional profiles predictive of the clinical benefit of cisplatin and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic biopsy samples from 96 CF-treated metastatic gastric cancer patients were prospectively collected before therapy and analyzed using high-throughput transcriptional profiling and array comparative genomic hybridization. Transcriptional profiling identified 917 genes that are correlated with poor patient survival after CF at
P
<0.05 (poor prognosis signature), in which protein synthesis and DNA replication/recombination/repair functional categories are enriched. A survival risk predictor was then constructed using genes, which are included in the
poor prognosis signature
and are contained within identified genomic amplicons. The combined expression of three genes—
MYC
,
EGFR
and
FGFR2
—was an independent predictor for overall survival of 27 CF-treated patients in the validation set (adjusted
P
=0.017), and also for survival of 40 chemotherapy-treated gastric cancer patients in a published data set (adjusted
P
=0.026). Thus, combined expression of
MYC
,
EGFR
and
FGFR2
is predictive of poor survival in CF-treated metastatic gastric cancer patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21173787</pmid><doi>10.1038/tpj.2010.87</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-269X |
| ispartof | The pharmacogenomics journal, 2012-04, Vol.12 (2), p.119-127 |
| issn | 1470-269X 1473-1150 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3321506 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | 631/208/191/2018 692/699/67/1059/99 692/699/67/1504/1829 Aged Antineoplastic Agents - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Care and treatment Chemotherapy Clinical outcomes Female Gene Expression Genes, myc Genetic aspects Health aspects Human Genetics Humans Male Neoplasm Metastasis Oncology Original original-article Pharmacotherapy Prognosis Prospective Studies Psychopharmacology Receptor, Epidermal Growth Factor - genetics Receptor, Fibroblast Growth Factor, Type 2 - genetics Risk factors Stomach cancer Stomach Neoplasms - drug therapy Stomach Neoplasms - genetics Stomach Neoplasms - pathology Survival Analysis Treatment Outcome |
| title | Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A58%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Three-gene%20predictor%20of%20clinical%20outcome%20for%20gastric%20cancer%20patients%20treated%20with%20chemotherapy&rft.jtitle=The%20pharmacogenomics%20journal&rft.au=Kim,%20H%20K&rft.date=2012-04-01&rft.volume=12&rft.issue=2&rft.spage=119&rft.epage=127&rft.pages=119-127&rft.issn=1470-269X&rft.eissn=1473-1150&rft_id=info:doi/10.1038/tpj.2010.87&rft_dat=%3Cgale_pubme%3EA285207846%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=940981275&rft_id=info:pmid/21173787&rft_galeid=A285207846&rfr_iscdi=true |